Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06008197 · ClinicalTrials.gov registry record · Phase 3

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

A Phase 3 study of Heart Failure and Acute Heart Failure, sponsored by Colorado Prevention Center.

Recruiting
Registry status
Phase 3
Development phase
5,200
Enrollment target
20
Study locations

NCT06008197 is a Phase 3 study of Heart Failure and Acute Heart Failure that is actively recruiting participants, run by Colorado Prevention Center. The registered enrollment target is 5,200 participants, above the 2,036-participant average among 397 other Heart Failure trials with a reported enrollment target (155% higher). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06008197, a Phase 3 study of Heart Failure and Acute Heart Failure, is actively recruiting participants, sponsored by Colorado Prevention Center.

RECRUITING
Registry status
Phase 3
Development phase
5,200 participants
Enrollment target
20
Study locations

Study Summary

Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

Conditions Studied

Heart Failure Acute Heart Failure

Interventions

  • DRUG Placebo
  • DRUG Finerenone

Study Locations (20)

Indiana

  • Indianapolis, IN Investigative Site 10074 - Indianapolis
  • Indianapolis, IN Investigative Site 10008 - Indianapolis
  • Merrillville, IN Investigative Site 10064 - Merrillville

Kentucky

  • Louisville, KY Investigative Site 10006 - Louisville
  • Louisville, KY Investigative Site 10086 - Louisville
  • Paducah, KY Investigative Site 10079 - Paducah

California

  • Huntington Beach, CA Investigative Site 10031 - Huntington Beach
  • Los Angeles, CA Investigative Site 10089 - Los Angeles

Florida

  • Brooksville, FL Investigative Site 10077 - Brooksville
  • Miramar, FL Investigative Site 10113 - Miramar

Ohio

  • Centerville, OH Investigative Site 10119 - Centerville
  • Cincinnati, OH Investigative Site 10088 - Cincinnati

Arizona

  • Glendale, AZ Investigative Site 10096 - Glendale

Idaho

  • Boise, Idaho Investigative Site 10073 - Boise

Illinois

  • Chicago, IL Investigative Site 10062 - Chicago

Trial Details

FieldValue
Enrollment Target 5,200 participants
Start Date 2024-01-17
Est. Completion 2027-12
Phase Phase 3

Sponsor

Colorado Prevention Center

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06008197

The ClinicalTrials.gov registry entry for NCT06008197 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,036-participant average among 397 other Heart Failure trials with a reported enrollment target (155% higher). The listed sponsor is Colorado Prevention Center, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06008197 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Indiana, Kentucky, California.

Frequently Asked Questions

What is clinical trial NCT06008197 about?

NCT06008197 is a clinical study titled "A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients". Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.

What is the current status of trial NCT06008197?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,200 participants. The study started on 2024-01-17. Estimated completion is 2027-12.

What conditions does trial NCT06008197 study?

This clinical trial studies the following conditions: Heart Failure, Acute Heart Failure.

What interventions are being tested in trial NCT06008197?

The interventions under investigation include: Placebo (DRUG), Finerenone (DRUG).

Who is sponsoring clinical trial NCT06008197?

This trial is sponsored by Colorado Prevention Center, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06008197 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Idaho, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure

All registered trials for this condition

Acute Heart Failure

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.